6.7 Cranial CT scan. 
6.8 An abdominal CT scan will be obtained if the patient has abnormal liver 
function tests or an elevated LDH. 
6.9 Peripheral blood will be obtained for immune assays (six green top tubes 
and two red top tubes). These will be stored in the laboratories of Drs. 
Gansbacher and Houghton. 
6.10 Additional tests, x-rays and scans as indicated by the patient’s presenting 
signs and symptoms and required to define the extent of the patient’s 
disease. 
TREATMENT PLAN 
7. 1 Patients will receive at least four vaccinations. The first six patients will 
receive a low dose vaccination (defined below). The subsequent six will 
receive the higher dose level of vaccine. The vaccine will consist of 
irradiated, allogenic SK-MEL-29 tumor cells that have been engineered to 
secrete IL-2. 
Low Dose: Approximately 10 million tumor cells 
High Dose: Approximately 50 million tumor cells 
7.2 A series of four vaccinations will be given either subcutaneously into the 
thigh or the arm of the patient. The sites will vary with each vaccination. 
A limb that has undergone a lymph node dissection will not be used for 
vaccination sites. One vaccination will be given every two weeks for four 
weeks. A booster vaccination will be given two months following the 
third vaccination. If a patient has a clinical major response (PR or CR as 
defined in section 10.0), additional boosters will be given every three 
months for one year or until progression of disease. Vaccination may 
continue beyond one year in responding patients at the discretion of the 
Principal Investigators. Patients with minor responses or stable disease 
will receive boosters at the discretion of the principal investigators up to 
one year. Blood work will be obtained prior to each vaccination (see 
section 8.0). 
Vaccinate: Day 1, 15, 29, 85 
7.3 If a patient develops a severe reaction as defined as grade 4 toxicity (see 
section 11.0) to the vaccine or deteriorating performance status 
Recombinant DNA Research, Volume 15 
